# A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis

> **NCT06085521** · PHASE2 · COMPLETED · sponsor: **Lynk Pharmaceuticals Co., Ltd** · enrollment: 150 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** LNK01001 Dose A
- **DRUG:** LNK01001 Dose B
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT06085521
- **Lead sponsor:** Lynk Pharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-26
- **Primary completion:** 2023-06-14
- **Final completion:** 2023-06-14
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2023-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06085521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06085521, "A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06085521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*